Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical study

The quality, pharmacokinetic and pharmacodynamic profiles, safety and immunogenicity must be compared to demonstrate the bio-similarities of recombinant human insulin and insulin analogues. To confirm these bio-similarities in clinical studies, it is necessary to adhere to a multi-phased approach, starting with the pharmacokinetics and pharmacodynamics of the study drugs. In this article, in accordance with modern approaches to drug research, evaluation of the pharmacokinetics and pharmacodynamics of recombinant human insulin and analogues of human insulin (biosimilar drugs) is performed in a double-blind, randomised crossover euglycaemic hyperinsulinaemic clamp study.

This article describes the main approaches to the evaluation of the pharmacokinetic and pharmacodynamic parameters of recombinant human insulin preparations and insulin analogues during a euglycaemic hyperinsulinaemic clamp study. The inclusion criteria for the sample selection, design and conditions of the study, methods for the suppression of endogenous insulin, recommendations for doses of drugs, duration of the study and choice of primary and secondary pharmacokinetic and pharmacodynamic parameters for bio-similar insulin products (which depend on the duration of their effects) are described.

1. Дедов И.И. Инновационные технологии в лечении и профилактике сахарного диабета и его осложнений // Сахарный диабет. – 2013. – Т. ١٦. – №3 – C. 4-10. [Dedov II. Novel technologies for the treatment and prevention of diabetes mellitus and its complications. Diabetes mellitus. 2013;16(3):4-10. (in Russ)]. doi: 10.14341/2072-0351-811

2. The Commission of the European Communities (2003) Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use. In Official Journal of the European Union. (L159):46-94. Available from: http://eur-lex.europa.eu/Lex-UriServ/LexUriServ.do?uri=OJ:L:2003:159:0046:0094:EN:PDF

3. Шестакова М.В., Викулова О.К. Биосимиляры: презумпция виновности?. // Сахарный диабет. – 2011. – Т. ١٤. – №4 – C. 91-99. [Shestakova MV, Vikulova OK. Biosimilars: presumption of guilt. Diabetes mellitus. 2011;14(4):91-99. (in Russ)]. doi: 10.14341/2072-0351-5825

4. Миронов А.Н., Горячев Д.В., Проскурина И.А., Меркулов В.А. Экспертные подходы к оценке отношения ожидаемой пользы к возможному риску применения биоаналогичных препаратов генно-инженерного человеческого инсулина и его аналогов // Ведомости НЦЭСМП. — ٢٠١٤. — №٣ — С. 3-8. [Mironov AN, Goryachev DV, Proskurina IA, Merkulov VА. Expert approaches to assessing benefit-risk ratio of biosimilar genetically engineered human insulin preparations and its analogues. Scientific Centre for Expert Evaluation of Medicinal Products Bulletin. 2014;(3):3-8. (in Russ)]

5. Annex guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues-guidance on biosimilar medicinal products containing recombinant human insulin (EMEA/CHMP/32775/2005). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003957.pdf

6. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. European Medicines Agency. 2006. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf.

7. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues (EMEA/CHMP/BMWP/32775/2005_Rev. 1). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500184161.pdf

8. Стратегия развития фармацевтической промышленности Российской Федерации на период до ٢٠٢٠ года (утверждена приказом Минпромторга России от ٢٣ октября ٢٠٠٩). [Strategiya razvitiya farmatsevticheskoy promyshlennosti Rossiyskoy Federatsii na period do 2020 goda (utverzhdena prikazom Minpromtorga Rossii of 23 October 2009). (in Russ)].] Available on URL: http://pharma2020.ru.

9. Федеральный закон Российской Федерации от ٢٢ декабря ٢٠١٤ г. N ٤٢٩-ФЗ «О внесении изменений в Федеральный закон «Об обращении лекарственных средств» [Принят Государственной Думой ٩ декабря ٢٠١٤ года. Одобрен Советом Федерации ١٧ декабря ٢٠١٤ года. Вступает в силу: 1 июля 2015 г.]. // Российская газета. Федеральный выпуск. 26 декабря 2010: (6568). [Federal’nyy zakon Rossiyskoy Federatsii of 22 december 2014. N 429-FZ «O vnesenii izmeneniy v Federal’nyy zakon «Ob obrashchenii lekarstvennykh sredstv» [Prinyat Gosudarstvennoy Dumoy 9 december 2014.Odobren Sovetom Federatsii 17 december 2014. Vstupaet v silu: 1 july 2015]. Rossiyskaya gazeta. Federal’nyy vypusk. 2010 December 26:(6568). (in Russ)].

10. Руководство по экспертизе лекарственных средств. (Том IV) — М.: ПОЛИГРАФ-ПЛЮС; ٢٠١٤. [Rukovodstvo po ekspertize lekarstvennykh sredstv. (Vol IV). Moscow: POLIGRAF-PLUS; 2014. (in Russ)].

11. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237(3):E214-223.

12. Майоров А.Ю., Урбанова К.А., Галстян Г.Р. Методы количественной оценки инсулинорезистентности // Ожирение и метаболизм. — 2009. — Т. 6. — №2 — C. 19-23. [Mayorov AY, Urbanova KA, Galstyan GR. Methods for guantificative assessment of insulin resistance. Obesity and metabolism. 2009;6(2):19-23. (in Russ)]. doi: 10.14341/2071-8713-5313

13. Ayala JE, Bracy DP, Malabanan C, et al. Hyperinsulinemic-euglycemic clamps in conscious, unrestrained mice. J Vis Exp. 2011(57). pii: 3188. doi: 10.3791/3188

14. Yeung EH, Zhang C, Mumford SL, et al. Longitudinal study of insulin resistance and sex hormones over the menstrual cycle: the BioCycle Study. J Clin Endocrinol Metab. 2010;95(12):5435-5442. doi: 10.1210/jc.2010-0702

15. Thatcher MO, Tippetts TS, Nelson MB, et al. Ceramides mediate cigarette smoke-induced metabolic disruption in mice. Am J Physiol Endocrinol Metab. 2014;307(10):E919-927. doi: 10.1152/ajpendo.00258.2014

16. European Medicines Agency. Clinical investigation of the pharmacokinetics of therapeutic proteins. Available from:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003029.pdf

17. The United States Food and Drug Administration. Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product [Draft Guidance for Industry]. Available from:http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM397017.pdf

18. Swinnen SG, Holleman F, DeVries JH. The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. Diabetologia. 2008;51(10):1790-1795. doi: 10.1007/s00125-008-1098-5

19. European Medicines Agency. Investigation of bioequivalence. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf

20. Chow SC, Liu J. Design and Analysis of Bioavailability and Bioequivalence Studies. 3rd edition. Boca Raton: Chapman & Hall Crc Press; 2009.